Literature DB >> 28040276

Clinical impact of complete revascularization in elderly patients with multi-vessel coronary artery disease undergoing percutaneous coronary intervention: A sub-analysis of the SHINANO registry.

Mikiko Harada1, Takashi Miura2, Takahiro Kobayashi3, Hideki Kobayashi2, Masanori Kobayashi4, Hiroyuki Nakajima5, Hikaru Kimura6, Hiroshi Akanuma7, Eiichiro Mawatari8, Toshio Sato9, Shoji Hotta10, Yuichi Kamiyoshi11, Takuya Maruyama12, Noboru Watanabe13, Takayuki Eisawa14, Naoto Hashizume12, Soichiro Ebisawa2, Yusuke Miyashita15, Uichi Ikeda16.   

Abstract

BACKGROUND: Prior reports have revealed that complete revascularization (CR) by percutaneous coronary intervention (PCI) decreased ischemic events. However, little is known about the efficacy of CR using PCI in elderly patients with multi-vessel coronary artery disease (CAD). We evaluated the 1-year effectiveness of CR-PCI in elderly patients (≥75years old) with multi-vessel CAD.
METHODS: The SHINANO Registry, a prospective, observational, multi-center, all-comer cohort study, has enrolled 1923 patients. From this registry, we recruited 322 elderly patients with multi-vessel CAD. The primary endpoint was major adverse cardiovascular events ([MACE]: all-cause mortality, myocardial infarction, and stroke).
RESULTS: Of the 322 elderly patients with multi-vessel CAD, 165 (51.2%) received CR and 157 (48.8%) received incomplete revascularization (ICR). MACE occurred in 44 (13.7%) patients. The incidence of MACE by survival analysis was significantly lower in the CR group than in the ICR group (7.4% vs. 21.1%, p<0.001). On multivariable Cox proportional hazards analysis of age, sex, and acute coronary syndrome (ACS), ACS and CR were independent predictors of MACE (hazard ratio [HR], 2.49; 95% confidence interval [CI], 1.29-4.80; p=0.007, HR, 0.40; 95% CI, 0.20-0.77; p=0.007, respectively). In propensity score matching of age, sex, previous heart failure, previous intracranial bleeding, ACS, and body mass index, the MACE rate was significantly lower in the CR group than in the ICR group (7.2% vs. 18.4%, p=0.015).
CONCLUSIONS: Even in elderly patients over 75years old with multi-vessel CAD, CR-PCI appears to suppress mid-term ischemic events.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Complete revascularization; Elderly; Major adverse cardiovascular events; Multi-vessel coronary artery disease; Percutaneous coronary intervention

Mesh:

Year:  2016        PMID: 28040276     DOI: 10.1016/j.ijcard.2016.12.093

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  3 in total

1.  Effects of complete revascularization on long-term treatment outcomes in patients with multivessel coronary artery disease over 80 years of age admitted for acute coronary syndrome.

Authors:  Kirill Berezhnoi; Leonid Kokov; Alexandr Vanyukov
Journal:  Cardiovasc Diagn Ther       Date:  2019-08

2.  Relationship between long non-coding RNA and prognosis of patients with coronary heart disease after percutaneous coronary intervention: A protocol for systematic review and meta-analysis.

Authors:  Fei Wang; Xiaoqing Cai; Piqi Jiao; Yan Liu; Bin Yuan; Peng Zhang; Hongbin Liu; Ling Ma
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

3.  Prognostic stratification of older patients with multivessel coronary artery disease treated with percutaneous transluminal coronary angioplasty based on clinical and biochemical measures: protocol for a prospective cohort study.

Authors:  Ada Del Mar Carmona-Segovia; María Victoria Doncel-Abad; Víctor M Becerra-Muñoz; Jorge Rodríguez-Capitán; Fernando Sabatel-Pérez; María Flores-López; María José Sánchez-Quintero; Dina Medina-Vera; Ana Isabel Molina-Ramos; Rajaa El Bekay; José Miguel Morales-Asencio; María Angullo-Gómez; Luis García-Rodríguez; Lucía Palma-Martí; Francisco Javier Pavón-Morón; Manuel F Jiménez-Navarro
Journal:  BMJ Open       Date:  2022-02-28       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.